Low Grade Serous Ovarian Carcinoma Market

Market Overview:

The 7 major low grade serous ovarian carcinoma markets reached a value of US$ 179.6 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 363.7 Million by 2034, exhibiting a growth rate (CAGR) of 6.62% during 2024-2034.

The low grade serous ovarian carcinoma market has been comprehensively analyzed in IMARC's new report titled "Low Grade Serous Ovarian Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Low grade serous ovarian carcinoma (LGSOC) refers to a rare subtype of epithelial ovarian cancer that grows slowly and has a relatively better prognosis compared to other types of ovarian cancer. It is characterized by the presence of small, uniform tumor cells that form glandular structures. The common symptoms of this condition include chronic stomach pain, difficulty eating, bloating, changes to bowel movements, urinary urgency, etc. Individuals suffering from LGSOC may also experience a sudden feeling of fullness, reduced appetite, and pain in the stomach, back, and pelvis. The diagnosis of the ailment typically requires a combination of clinical examination, medical history, and a pelvic test. A CA125 blood workup, which can detect a protein in the body that is a cancer marker, is further utilized for disease detection among patients. The healthcare provider may perform transvaginal ultrasound and computerized tomography scans to rule out other possible causes and confirm a diagnosis.

The rising prevalence of inherited genetic disorders, causing DNA abnormalities, gene variations, and chromosomal damage, is primarily driving the low grade serous ovarian carcinoma market. Furthermore, the increasing incidences of various associated risk factors, such as family history, obesity, past childbirth, pregnancy, advancing age, etc., are also augmenting the market growth. Apart from this, the widespread adoption of kinase inhibitors, including pertuzumab, afatinib, trastuzumab, etc., to reduce tumor cells and block disease progression among patients is further creating a positive outlook for the market. Additionally, the emerging popularity of real-time molecular profiling technologies, since they can support the management of the underlying ailment by identifying genetic mutations and other molecular abnormalities that cause LGSOC, is also bolstering the market growth. Moreover, the inflating utilization of cytoreductive surgery and platinum-based chemotherapy which enhance host immunological response, thereby eradicating cancer masses and improving overall survival, is acting as another significant growth-inducing factor. In addition to this, the escalating demand for biomarker testing and sequencing that help in early diagnosis, predict response to therapy, and monitor disease progression is expected to drive the low grade serous ovarian carcinoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the low grade serous ovarian carcinoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for low grade serous ovarian carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the low grade serous ovarian carcinoma market in any manner.

Recent Developments:

• In May 2024, Verastem Oncology announced that it had begun submitting a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for accelerated approval of the combination of avutometinib, an RAF/MEK clamp, and defactinib, a selective FAK inhibitor, for adult patients with recurrent KRAS mutant (KRAS mt) low-grade serous ovarian cancer (LGSOC) who have received at least one prior systemic therapy.
• In May 2024, eFFECTOR Therapeutics, Inc. announced a collaboration to launch an investigator-sponsored trial (IST) evaluating zotatifin in combination with abemaciclib and letrozole in patients suffering from estrogen receptor-positive (ER+) endometrial cancer and low grade serous ovarian cancer at the Dana-Farber Cancer Institute (DFCI).

Key Highlights:

• LGSOCs are rare and account for less than 5% of all ovarian cancer cases.
• This condition affects around 6,000 women in the United States and 80,000 people worldwide.
• LGSOC affects a younger patient population, having bimodal peaks at 20-30 and 50-60 years old, and has a median survival of about ten years.
• In Western countries, the prevalence of KRAS mutations in LGSOCs was reported to be between 16% and 44%, BRAF mutations between 2% and 20%, and NRAS mutations up to 26%.

Drugs:

Avutometinib is an RAF/MEK clamp that creates inactive complexes of MEK with ARAF, BRAF, and CRAF, potentially leading to a more comprehensive and long-lasting anti-tumor response via maximal RAS/MAPK pathway suppression. This novel approach enables avutometinib to suppress MEK signaling without causing compensatory MEK activation, which appears to restrict the efficacy of previous MEK-only inhibitors.

KEYTRUDA (pembrolizumab) is an anti-programmed death receptor-1 (PD-1) treatment that boosts the immune system's ability to detect and combat tumor cells. KEYTRUDA is a humanized monoclonal antibody that inhibits the interaction of PD-1 and its ligands, PD-L1 and PD-L2, activating T lymphocytes that can affect both tumor cells and healthy cells.

Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a type of medicine that slows the growth of cancer by blocking two proteins known as cyclin-dependent kinase 4 and 6. When these proteins are over-activated, cancer cells can proliferate and divide abnormally quickly. Targeting CDK4/6 with increased accuracy may help to ensure that cancer cells do not continue to multiply uncontrolled.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the low grade serous ovarian carcinoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the low grade serous ovarian carcinoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current low grade serous ovarian carcinoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the low grade serous ovarian carcinoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the low grade serous ovarian carcinoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the low grade serous ovarian carcinoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of low grade serous ovarian carcinoma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of low grade serous ovarian carcinoma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of low grade serous ovarian carcinoma by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with low grade serous ovarian carcinoma across the seven major markets?
• What is the size of the low grade serous ovarian carcinoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of low grade serous ovarian carcinoma?
• What will be the growth rate of patients across the seven major markets?
   

Low Grade Serous Ovarian Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for low grade serous ovarian carcinoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the low grade serous ovarian carcinoma market?
• What are the key regulatory events related to the low grade serous ovarian carcinoma market?
• What is the structure of clinical trial landscape by status related to the low grade serous ovarian carcinoma market?
• What is the structure of clinical trial landscape by phase related to the low grade serous ovarian carcinoma market?
• What is the structure of clinical trial landscape by route of administration related to the low grade serous ovarian carcinoma market?